Full Press Release Details
Reports Third Quarter 2025 Financial Results
Completes IPO, Expands Patent Portfolio, and Strengthens Board Independence -
AZ - November 14, 2025 - Picard Medical, Inc. (NYSE American: PMI) ("Picard" or the "Company"),
parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health
Canada, today announced financial results for the three and nine months ended September 30, 2025.
NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc., commented, "The third quarter marked a pivotal moment for the
company with the successful completion of its initial public offering in September. The IPO strengthened the balance sheet by retiring
convertible debt, providing new capital to accelerate research, development, and commercial expansion across SynCardia's life-saving
artificial heart platform."
Quarter and Recent Company Highlights
added, "In the third quarter, we continued to secure additional patent protection, underscoring our commitment to the life-saving
technology around our SynCardia Total Artificial Heart, or STAH, the most widely used and extensively studied artificial heart in the
world. We also welcomed Sam Van and George Ye to our board; both of whom have deep leadership experience in complementary areas to advise
the company in its next stage as a public company."
Third Quarter Driven by IPO Milestone and Revenue Growth
Medical completed its initial public offering (IPO) on September 2, 2025, raising approximately $19.5 million in gross proceeds
($15.5 million, net, after the underwriters of the offering exercised an overallotment option).
Growth and Improved Gross Margin
quarter revenue reached $1.19 million, a 35 percent increase from the third quarter of 2024, reflecting higher U.S. product sales and
a steady increase in driver rentals. Cost of revenue declined 15 percent year-over-year, reducing the gross loss by 81 percent to $0.13
expenses were $3.36 million, down 11 percent, driven by lower selling, general and administrative expenses. As a result, operating loss
narrowed to $3.36 million, compared to $3.77 million in the third quarter of 2024.
Performance for the Nine Months Ending September 30, 2025
the nine-month period ending September 30, 2025, revenue totaled $3.93 million, up 11 percent from 2024. Operating loss was $10.3
million, largely consistent with 2024 levels for the same period, as disciplined cost control offset higher materials and production
costs. Net loss of $22.7 million included non-cash charges of $12.4 million related to the revaluation of derivative liabilities associated
with convertible debt conversion at the time of the IPO.
| Jul-Sep | Jan-Sep | |||||||||||||||||||||||
| Key Figures in Summary ( 000) | 2025 | 2024 | % | 2025 | 2024 | % | ||||||||||||||||||
| Revenue | 1,187 | 881 | 34.7 | % | 3,931 | 3,555 | 10.6 | % | ||||||||||||||||
| Gross profit | (130 | ) | (673 | ) | -80.7 | % | (615 | ) | (248 | ) | 148.0 | % | ||||||||||||
| Gross margin, % | -12 | % | -76 | % | -16 | % | -7 | % | ||||||||||||||||
| EBITDA | (3,487 | ) | (4,444 | ) | -21.5 | % | (10,254 | ) | (10,140 | ) | 1.1 | % | ||||||||||||
| EBITDA margin, % | -313 | % | -504 | % | -266 | % | -290 | % | ||||||||||||||||
| Derivative Loss & Interest | (6,939 | ) | (1,762 | ) | 0.0 | % | - | - | 0.0 | % | ||||||||||||||
| EBIT (Operating profit/loss) | (10,426 | ) | (6,206 | ) | -80.7 | % | (615 | ) | (248 | ) | 148.0 | % | ||||||||||||
| EBIT margin, % | -12 | % | -76 | % | 0 | % | -16 | % | -7 | % | ||||||||||||||
| Cash flows from Operating Activities | (6,514 | ) | (2,608 | ) | -149.8 | % | (11,296 | ) | (2,608 | ) | -333.1 | % | ||||||||||||
| Earnings per share (EPS) | (0.19 | ) | (0.87 | ) | 77.9 | % | (0.96 | ) | (1.79 | ) | 46.6 | % |
| Sep-25 | Jun-25 | Sep-25 | Jun-25 | |||||||||||||
| Debt paid at IPO | - | 8,248 | - | 8,248 | ||||||||||||
| Debt converted into equity at IPO | - | 18,245 | - | 18,245 | ||||||||||||
| Equity ratio, % | 59 | % | -291 | % | 59 | % | -291 | % |
Picard Medical and SynCardia
Medical, Inc. is the parent company of SynCardia Systems, LLC ("SynCardia"), the Tucson, Arizona-based leader with
the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures,
and commercializes the SynCardia Total Artificial Heart ("STAH"), an implantable system that assumes the full functions of
a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only
commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across
27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
additional information about Picard Medical, please visit www.picardmedical.com or review the Company's filings
with the U.S. Securities and Exchange Commission at www.sec.gov.
press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that
are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to
differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates
or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto
or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous
conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration
Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's
website, http://www.sec.gov.
Medical, Inc./SynCardia Systems, LLC